Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PARIS, FRANCE AND NEW YORK, USA , JULY 23, 2026 (GLOBE NEWSWIRE) -- PARIS, FRANCE AND NEW YORK, USA, JULY 23, 2026  CYLLENE THERAPEUTICS (CYLLENE TX), THE GLOBAL LEADER IN NON-REPLICATING HSV-1 (NRHSV-1) VECTOR TECHNOLOGY IN NEUROLOGY, TODAY ANNOUNCED THE APPOINTMENT OF ALYSSA LEVIN TO ITS BOARD OF DIRECTORS, WHERE SHE WILL ALSO SERVE AS CHAIR OF THE AUDIT COMMITTEE. THE COMPANY HAS ALSO STRENGTHENED ITS LEADERSHIP TEAM WITH TWO KEY ADDITIONS. CLARA CAMBON-THIEBAUD JOINS AS VICE PRESIDENT, REGULATORY AFFAIRS, BASED IN NEW YORK, AND CLINE BREDA AS VICE PRESIDENT, CHEMISTRY MANUFACTURING AND CONTROLS (CMC). THIS LEADERSHIP TEAM EXPANSION COMES AS CYLLENE TX ADVANCES ITS LEAD CANDIDATE, EG110A, TOWARDS LATE-STAGE CLINICAL DEVELOPMENT FOR NEUROGENIC BLADDER-RELATED INCONTINENCE.

CYLLENE THERAPEUTICS EXPANDS LEADERSHIP TEAM TO SUPPORT CORPORATE GROWTH AND CLINICAL PRODUCT DEVELOPMENT

AT 2 P.M. ET ON TUESDAY, JUNE 30TH, NKARTA PRESIDENT NADIR MAHMOOD WILL TAKE PART IN A FIRESIDE AT THE H.C. WAINWRIGHT CELL THERAPY VIRTUAL CONFERENCE.

NKARTA TO PARTICIPATE IN H.C. WAINWRIGHT 4TH ANNUAL CELL THERAPY VIRTUAL CONFERENCE

ENROLLMENT ONGOING AT 4 BILLION CELL DOSE LEVEL (12 BILLION CELLS IN 3-DOSE CYCLE) ACROSS ALL INDICATIONS IN NTRUST-1 AND NTRUST-2 REGULATORY AGREEMENT SUPPORTS EXPANSION INTO COMMUNITY-BASED SETTINGS WITH OUTPATIENT DOSING TO REDUCE PATIENT BURDEN INITIAL CLINICAL DATA FROM NTRUST-1 AND NTRUST-2 EXPECTED TO BE PRESENTED AT A MEDICAL MEETING IN 2026 CASH BALANCE OF $266.7 MILLION ON MARCH 31, 2026, INCLUDING CASH, CASH EQUIVALENTS AND INVESTMENTS, EXPECTED TO FUND OPERATIONS INTO 2029 SOUTH SAN FRANCISCO, CALIF., MAY 12, 2026 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

NKARTA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SOUTH SAN FRANCISCO, CALIF., APRIL 15, 2026 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT IT HAS REACHED AGREEMENT WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON KEY CHANGES TO THE ONGOING NTRUST-1 AND NTRUST-2 CLINICAL TRIALS. THE PROTOCOL AMENDMENTS ARE DESIGNED TO ALLEVIATE THE NEED FOR OVERNIGHT STAYS AND REDUCE THE OVERALL BURDEN ON PATIENTS, ENABLING OUTPATIENT ADMINISTRATION OF NKX019  AN INVESTIGATIONAL CAR-NK CELL THERAPY  BY COMMUNITY RESEARCH CENTERS AND COMMUNITY RHEUMATOLOGISTS.

NKARTA ANNOUNCES FDA AGREEMENT ON OUTPATIENT DOSING OF NKX019 IN AUTOIMMUNE DISEASE, EXPANDING ACCESS TO COMMUNITY RHEUMATOLOGY CENTERS

SOUTH SAN FRANCISCO, CALIF., APRIL 09, 2026 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE.

NKARTA TO PARTICIPATE IN NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

SOUTH SAN FRANCISCO, CALIF., MARCH 25, 2026 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2025. 2025 WAS A YEAR OF STRATEGIC IMPORTANCE FOR NKARTA AS WE ONBOARDED A CLINICAL TEAM WITH DEEP AUTOIMMUNE EXPERIENCE, RIGHT-SIZED OUR WORKFORCE TO BE A RESPONSIBLE STEWARD OF INVESTOR CAPITAL, AND CONTINUED TO ADVANCE OUR CAR-NK CELL THERAPY PLATFORM THROUGH DOSE ESCALATION IN THE CLINIC, SAID PAUL J. HASTINGS, CHIEF EXECUTIVE OFFICER OF NKARTA. THOUGHTFULLY LEVERAGING OUR SAFETY DATA, WE ARE NOW DOSING PATIENTS AT 4 BILLION CELLS IN A THREE-DOSE CYCLE FOR A TOTAL OF 12 BILLION CELLS AS WE LOOK TO MAXIMIZE THE DEPTH AND DURABILITY OF B-CELL DEPLETION AND CLINICAL RESPONSE, POSITIONING US TO UNLOCK THE FULL POTENTIAL OF NKX019 FOR PEOPLE LIVING WITH AUTOIMMUNE DISEASE.

NKARTA REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SOUTH SAN FRANCISCO, CALIF., FEB. 27, 2026 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES:

NKARTA TO PARTICIPATE IN MARCH INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF., DEC. 02, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE EVERCORE 8TH ANNUAL HEALTHCARE CONFERENCE ON THURSDAY IN MIAMI.

NKARTA TO PARTICIPATE IN EVERCORE HEALTHCARE CONFERENCE

ENROLLMENT NOW UNDERWAY IN SECOND DOSE-ESCALATION COHORT DEEP B-CELL DEPLETION OBSERVED IN ALL PATIENTS TREATED TO DATE WHO RECEIVED NKX019 WITH LYMPHODEPLETION USING FLUDARABINE AND CYCLOPHOSPHAMIDE VERSUS PARTIAL B-CELL DEPLETION IN PATIENTS RECEIVING ONLY CYCLOPHOSPHAMIDE ENROLLMENT STREAMLINED ACROSS NTRUST-1 AND NTRUST-2 UNDER A COMBINED INDEPENDENT DATA SAFETY MONITORING BOARD (IDSMB) TO GUIDE DOSE ESCALATION INITIAL DATA FOR NKX019 IN MULTIPLE AUTOIMMUNE INDICATIONS EXPECTED TO BE PRESENTED AT A MEDICAL CONFERENCE IN 2026 CASH BALANCE OF $316.5 MILLION ON SEPTEMBER 30, 2025, INCLUDING CASH, CASH EQUIVALENTS, AND INVESTMENTS, EXPECTED TO FUND OPERATIONS INTO 2029 SOUTH SAN FRANCISCO, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

NKARTA REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SOUTH SAN FRANCISCO, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES, TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES NEXT MONTH:

Nkarta, Inc.

NKTX

Price

Financial Reports

No items found.

Press Releases

Nkarta, Inc.

NKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NKTX